Status:
UNKNOWN
The Effect and Mechanism of MMP-9 in Inducing Atherosclerosis
Lead Sponsor:
Majianhua
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-80 years
Brief Summary
The study will assess the serum expression of MMP-9 in normal people, type 2 diabetic patients and type 2 diabetic patients with atherosclerosis.
Eligibility Criteria
Inclusion
- volunteer to participate and be able to sign informed consent prior to the trial.
- patients with type 2 diabetes, aged 18-60 years old, meeting WHO1999 diagnostic criteria, have not used any drugs.
- The patients have completed carotid ultrasound during hospitalization.
Exclusion
- patients with any antidiabetic drugs.
- impaired liver and kidney function with ALT 2.5 times higher than the upper limit of normal value; Serum creatinine was 1.3 times higher than the upper limit of normal.
- drug abuse and alcohol dependence in the past 5 years.
- systemic hormone therapy was used in the last three months.
- patients with infection and stress within 4 weeks.
- any other obvious conditions or associated diseases determined by the researcher: such as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors and other diseases, other pancreatic diseases, history of mental diseases.
Key Trial Info
Start Date :
June 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2020
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04424706
Start Date
June 30 2020
End Date
December 30 2020
Last Update
June 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing First Hospital
Nanjing, Jiangsu, China